Dendritic cell vaccine - Renovaro Biosciences
Alternative Names: ENO-4001; ENOB-DB-01; MCV - Renovaro Biosciences; MelCancerVacLatest Information Update: 21 Aug 2023
At a glance
- Originator DanDrit Biotech A/S
- Developer Renovaro Biosciences
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 09 Aug 2023 Enochian BioSciences is now called Renovaro Biosciences
- 09 Aug 2019 Discontinued - Phase-II for Colorectal cancer in Singapore (Intradermal) (Enochian BioSciences pipeline, August 2019)
- 09 Aug 2019 Discontinued - Phase-II for Non-small cell lung cancer in Denmark (SC) (Enochian BioSciences pipeline, August 2019)